Active Ingredient
Tolnaftate 1%
Suai Fungus Nail Treatment Liquid
FDA Label NDC 83809-017
Full FDA labeling including Indications, Dosage, Usage, and Precautions
Structured Product Label
The following Structured Product Label (SPL) was submitted to the FDA by Shenzhen Yikai Electronic Technology Co., Ltd. for the product Suai Fungus Nail Treatment Liquid (NDC 83809-017). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding active ingredient, use, warnings, keep oot of reach of children, directions, other information, inactive ingredients, principal display panel, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
Label Section Quick Index
Use
for relief and treatment of pain, soreness, and inflammation from nail
fungus. Symptoms:
■discolored nails
■brittle nails
■distorted nails
Warnings
For external use only. Some individuals may be sensitive to essential oils. Begin with a small drop to determine if product causes any irritation. Discontinue use if any irritation occurs. Stop use and consult a doctor if condition worsens. Not for use on children under the age of 2 without physician direction.
Keep Oot Of Reach Of Children
If pregnant or breast-feeding, ask a health professional before use. If accidental ingestion and adverse reaction occurs, get medical help or contact a Poison Control Center.
Directions
shake well before use. Wash and thoroughly dry the affected area. Apply 1-2 drops and gently rub into affected area three times per day. Wash hands after applying.
Other Information
*Keep in cool dark place
*Store upright
*Tighten cap after use to prevent
oxidation
Inactive Ingredients
Water,Lonicerae Japonicae flos,Angelicae,Glycerin, Allantoin, Garlic Extract, Tea Tree Oil.
Principal Display Panel
.jpg "001(1).jpg")
1 (001(1))
2 (002)
3 (003)
.jpg "004(1).jpg")
4 (004(1))
* Please review the disclaimer below.
